Advertisement

Topics

Galapagos NV: Galapagos announces ISABELA Phase 3 program in IPF

16:02 EDT 12 Apr 2018 | FinanzNachrichten

Mechelen, Belgium; 12 April 2018, 22.01 CET - Galapagos announces the design of a worldwide Phase 3 program, based on feedback from the FDA and EMA, to evaluate GLPG1690 in patients with idiopathi...

Original Article: Galapagos NV: Galapagos announces ISABELA Phase 3 program in IPF

NEXT ARTICLE

More From BioPortfolio on "Galapagos NV: Galapagos announces ISABELA Phase 3 program in IPF"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...